ifosfamide has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 193 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation." | 9.12 | Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007) |
| "Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma." | 9.08 | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995) |
| "A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)." | 7.71 | Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 6.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| " Dosing was modified for elderly patients." | 5.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease." | 5.28 | Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991) |
| "A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation." | 5.12 | Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007) |
| " Relapsing progressive lymphoma patients (n = 204; non-Hodgkin's lymphoma n = 166; Hodgkin's disease n = 38) were, after induction treatment with the DHAP-VIM (cisplatin, cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate) regimen, randomly (2:1) assigned to the harvest of granulocyte-macrophage colony-stimulating factor-mobilized stem cells after the second DHAP course or autologous bone marrow cells before the second DHAP course." | 5.09 | Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. ( Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ, 2001) |
| "Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma." | 5.08 | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995) |
| "Seventy-two patients with recurrent or refractory malignant lymphoproliferative diseases were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) and concurrent mesna to prevent urothelial toxicity; 41 patients had high/intermediate-grade non-Hodgkin's lymphoma (NHL), 18 low-grade NHL/chronic lymphocytic leukemia (CLL), and 13 Hodgkin's disease (HD)." | 5.07 | MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. ( Brincker, H; Mirza, MR, 1991) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)." | 3.71 | Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002) |
| " Three groups of patients were prospectively evaluated: Group I: 15 patients with Wegener's granulomatosis and 4 patients with severe scleritis received a single dose cyclophosphamide (15 mg/kg bw/day) and 250 mg prednisone i." | 3.70 | Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide). ( Jockenhövel, F; Kummer, G; Mann, K; Philipp, T; Reinhardt, W; Reinwein, D; Sauter, V; Uppenkamp, M; Witzke, O, 1999) |
| "Neuroblastomas, nephroblastomas, malignant mesenchymal tumors, including rhabdomyosarcomas, Ewing's sarcomas, osteosarcomas, brain tumors, and non-Hodgkin's lymphomas respond to ifosfamide monotherapy." | 3.69 | Ifosfamide in the treatment of pediatric malignancies. ( Behrendt, H; de Kraker, J; Michiels, E; van den Berg, H; Voûte, PA, 1996) |
| " Carfilzomib, an irreversible proteasome inhibitor, can overcome acquired rituximab-chemotherapy resistance and, when combined with R-ICE, improves outcomes in patients with R/R DLBCL." | 3.30 | Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P, 2023) |
| "Grade 3 and 4 infections occurred four times more frequently in the dose-dense arm." | 2.75 | Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. ( Chott, A; Drach, J; Fridrik, MA; Geissler, D; Greil, R; Hausmaninger, H; Krieger, O; Lang, A; Michlmayr, G; Oberaigner, W; Ulsperger, E, 2010) |
| " These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim." | 2.73 | A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. ( Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T, 2008) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 2.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| "Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities." | 2.70 | A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002) |
| " daily for 4 days, ifosfamide 1500 mg mixed with equal dosing of mesna continuously infused i." | 2.70 | DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). ( Coleman, M; Kaufman, TP; Leonard, J; Shuster, MW, 2001) |
| "A fast metabolism of TRO with a half-life of about 1 h was observed." | 2.70 | New insights into the clinical pharmacokinetics of trofosfamide. ( Brinker, A; Brüggemann, SK; Kisro, J; Letsch, C; Wagner, T, 2002) |
| " In older patients (> 60 years) the dosage of idarubicin and ifosfamide was reduced to 75% in the initial cycle." | 2.69 | DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. ( Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B, 1998) |
| "Evaluate response, duration of response, and toxicity of paclitaxel in combination with other drugs known to be effective in non-Hodgkin's lymphoma (NHL)." | 2.69 | Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 1999) |
| " There were no toxic deaths." | 2.69 | Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation. ( Cavenagh, JD; Eden, AG; Hughes, A; Kelsey, SM; Lamont, A; McBride, NC; Mills, MJ; Newland, AC; Ward, MC, 1999) |
| "Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses." | 2.69 | [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]. ( Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J, 1998) |
| " In parallel, patients with solid tumors or non-Hodgkin's lymphomas (n = 28) treated with etoposide (500 mg/m2), ifosfamide (1500 mg/m2) and cisplatin (150 mg/m2) and identical dosing of G-CSF were analyzed." | 2.68 | Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. ( Engelhardt, M; Henschler, R; Lange, W; Mertelsmann, R; Waller, C; Winkler, J, 1997) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | 2.68 | Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| " However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival." | 2.67 | EPIC: an effective low toxicity regimen for relapsing lymphoma. ( Ashley, S; Catovsky, D; Cunningham, D; Gore, ME; Hickish, T; Mansi, J; Nicolson, V; Roldan, A; Smith, IE, 1993) |
| "Ifosfamide is an alkylating agent with a broad spectrum of activity in solid tumors and hematological malignancies." | 2.42 | Ifosfamide in hematological malignancies of adults. ( Elice, F; Rodeghiero, F, 2003) |
| "Ifosfamide has been used extensively for the treatment of patients with non-Hodgkin's lymphoma (NHL)." | 2.39 | Ifosfamide in the treatment of non-Hodgkin's lymphoma. ( Pohlman, B, 1996) |
| " Sequential dosing protocols, administration of high-dose chemotherapy with peripheral blood progenitor cell support, and other approaches, possibly combining current treatment options, may be necessary to further improve the long-term survival of patients with relapsed NHL." | 2.39 | Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. ( Vose, JM, 1996) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "Ifosfamide has been shown to have significant single-agent activity against non-Hodgkin's lymphoma and its use in various combinations produces response rates of 20% to 83% in patients with refractory or relapsing disease." | 2.38 | New perspectives in the treatment of non-Hodgkin's lymphoma. ( Goss, PE, 1992) |
| " The predictive capability of a published nomogram is restricted by differences in dosage regimens and encephalopathic classifications." | 2.38 | Ifosfamide-induced neurotoxicity: a case report and review of the literature. ( Eaton, VE; Miller, LJ, 1992) |
| "As salvage therapy in non-Hodgkin's lymphoma (NHL), IMV-Bleo (ifosfamide, methotrexate, etoposide, bleomycin) produced a complete remission (CR) rate of 41% and seemed to be particularly effective in patients with suboptimal response to first-line treatment." | 2.38 | European experience with ifosfamide in lymphomas. ( Diehl, V; Schaadt, M; von Kalle, AK, 1989) |
| " The purpose of this study was to explore the efficacy and safety of programmed cell death 1 (PD-1) blockade combined with ICE regimen (P-ICE) in the treatment of R/R DLBCL patients." | 1.91 | PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma. ( Bai, B; Gao, Y; He, Y; Huang, C; Huang, H; Ping, L; Shi, L; Wang, X, 2023) |
| " Dosing was modified for elderly patients." | 1.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "Of the classical Hodgkin lymphoma patients, the ORR were 72." | 1.56 | Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. ( Li, J; Liu, Z; Mi, M; Wang, Y; Zhang, C; Zhang, L, 2020) |
| "The extrapolation of the Calvert formula has utility in calculating the CBDCA dosage for DeVIC ± R therapy, and therapeutic efficacy was increased by maintaining the AUC of CBDCA at ≥4." | 1.43 | Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin ( Ando, M; Ando, Y; Emi, N; Hayashi, T; Inaguma, Y; Ito, K; Okamoto, A; Okamoto, M; Tomono, A; Tsuge, M; Yamada, S, 2016) |
| "Two patients with Hodgkin's lymphoma and two with non-Hodgkin's lymphoma who were undergoing stem cell therapy were studied." | 1.43 | Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. ( Arima, N; Fukunaga, A; Hyuga, M; Iwasaki, M; Kishimoto, W; Maesako, Y; Nakae, Y, 2016) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| "Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL)." | 1.33 | [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)." | 1.33 | IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005) |
| "Sites of relapse were designated as old (involved prior to HDCT) or new (previously uninvolved)." | 1.30 | High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy. ( Hallahan, D; Mundt, AJ; Williams, SF, 1997) |
| "Twelve patients with Hodgkin's disease (HD) and 38 patients with non-Hodgkin's lymphoma (NHL) were mobilized with MIME/G-CSF." | 1.30 | Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB, 1998) |
| "Epirubicin (Epi) was favored because of its low hemato- and cardiotoxicity [2]." | 1.29 | IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study. ( Gerhartz, HH; Walther, J; Wilmanns, W, 1993) |
| " The overall response rate of 41% might be improved by increased dosage and growth factor support." | 1.29 | Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma. ( Heinz, R; Hopfinger, G; Koller, E; Pittermann, E; Schneider, B, 1995) |
| "Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease." | 1.28 | Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (7.77) | 18.7374 |
| 1990's | 90 (46.63) | 18.2507 |
| 2000's | 63 (32.64) | 29.6817 |
| 2010's | 18 (9.33) | 24.3611 |
| 2020's | 7 (3.63) | 2.80 |
| Authors | Studies |
|---|---|
| Paszkiewicz-Kozik, E | 1 |
| Michalski, W | 1 |
| Taszner, M | 1 |
| Mordak-Domagała, M | 1 |
| Romejko-Jarosińska, J | 1 |
| Knopińska-Posłuszny, W | 1 |
| Najda, J | 1 |
| Borawska, A | 1 |
| Chełstowska, M | 1 |
| Świerkowska, M | 1 |
| Dąbrowska-Iwanicka, A | 1 |
| Malenda, A | 1 |
| Druzd-Sitek, A | 1 |
| Konecki, R | 1 |
| Kumiega, B | 1 |
| Osowiecki, M | 1 |
| Ostrowska, B | 1 |
| Szpila, T | 1 |
| Szymański, M | 1 |
| Targoński, Ł | 1 |
| Domańska-Czyż, K | 1 |
| Popławska, L | 1 |
| Giebel, S | 2 |
| Lange, A | 1 |
| Pluta, A | 1 |
| Zaucha, JM | 1 |
| Rymkiewicz, G | 1 |
| Walewski, J | 1 |
| Pavlovsky, M | 1 |
| Cubero, D | 1 |
| Agreda-Vásquez, GP | 1 |
| Enrico, A | 1 |
| Mela-Osorio, MJ | 1 |
| San Sebastián, JA | 1 |
| Fogliatto, L | 1 |
| Ovilla, R | 1 |
| Avendano, O | 1 |
| Machnicki, G | 1 |
| Barreyro, P | 1 |
| Trufelli, D | 1 |
| Villanova, P | 1 |
| Ping, L | 1 |
| Gao, Y | 1 |
| He, Y | 1 |
| Bai, B | 1 |
| Huang, C | 1 |
| Shi, L | 1 |
| Wang, X | 1 |
| Huang, H | 1 |
| Lin, LH | 1 |
| Ghasemi, M | 1 |
| Burke, SM | 1 |
| Mavis, CK | 1 |
| Nichols, JR | 1 |
| Torka, P | 1 |
| Mager, DE | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Goey, AKL | 1 |
| Behera, G | 1 |
| Purkait, S | 1 |
| Patra, S | 1 |
| Sasmal, PK | 1 |
| Majumdar, SKD | 1 |
| Das, DK | 1 |
| Naik, S | 1 |
| Singh, PK | 1 |
| Dangien, A | 1 |
| Ram-Wolff, C | 1 |
| Brice, P | 1 |
| Battistella, M | 1 |
| Roelens, M | 1 |
| Moins-Teisserenc, H | 1 |
| Peffault de Latour, R | 1 |
| Mourah, S | 1 |
| Bouaziz, JD | 1 |
| Lebbé, C | 1 |
| Bagot, M | 1 |
| de Masson, A | 1 |
| Mi, M | 1 |
| Zhang, C | 1 |
| Liu, Z | 1 |
| Wang, Y | 1 |
| Li, J | 1 |
| Zhang, L | 1 |
| Kim, SK | 1 |
| Song, MK | 1 |
| Chung, JS | 1 |
| Shin, HJ | 1 |
| Sun, H | 1 |
| Savage, KJ | 1 |
| Karsan, A | 1 |
| Slack, GW | 1 |
| Gascoyne, RD | 1 |
| Toze, CL | 1 |
| Sehn, LH | 1 |
| Abou Mourad, Y | 1 |
| Barnett, MJ | 1 |
| Broady, RC | 1 |
| Connors, JM | 1 |
| Forrest, DL | 1 |
| Gerrie, AS | 1 |
| Hogge, DE | 1 |
| Narayanan, S | 1 |
| Nevill, TJ | 1 |
| Nantel, SH | 1 |
| Power, MM | 1 |
| Sutherland, HJ | 1 |
| Villa, D | 1 |
| Shepherd, JD | 1 |
| Song, KW | 1 |
| Esbah, O | 1 |
| Tekgündüz, E | 1 |
| Şirinoğlu Demiriz, I | 1 |
| Civriz Bozdağ, S | 1 |
| Kaya, A | 1 |
| Tetik, A | 1 |
| Kayıkçı, Ö | 1 |
| Durgun, G | 1 |
| Kocubaba, Ş | 1 |
| Altuntaş, F | 1 |
| Park, S | 1 |
| Hong, J | 1 |
| Hwang, I | 1 |
| Ahn, JY | 1 |
| Cho, EY | 1 |
| Park, J | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Landsburg, DJ | 1 |
| Petrich, AM | 1 |
| Abramson, JS | 1 |
| Sohani, AR | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Chavez, JC | 1 |
| Song, K | 1 |
| Zelenetz, AD | 6 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Fenske, TS | 2 |
| Jaso, J | 1 |
| Medeiros, LJ | 1 |
| Yang, DT | 1 |
| Nabhan, C | 1 |
| Schorb, E | 1 |
| Finke, J | 1 |
| Ferreri, AJ | 1 |
| Ihorst, G | 1 |
| Mikesch, K | 1 |
| Kasenda, B | 1 |
| Fritsch, K | 1 |
| Fricker, H | 1 |
| Burger, E | 1 |
| Grishina, O | 1 |
| Valk, E | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Tomono, A | 1 |
| Ito, K | 1 |
| Hayashi, T | 1 |
| Ando, M | 1 |
| Ando, Y | 1 |
| Tsuge, M | 1 |
| Okamoto, A | 1 |
| Inaguma, Y | 1 |
| Okamoto, M | 4 |
| Emi, N | 1 |
| Yamada, S | 1 |
| Fukunaga, A | 1 |
| Hyuga, M | 1 |
| Iwasaki, M | 1 |
| Nakae, Y | 1 |
| Kishimoto, W | 1 |
| Maesako, Y | 1 |
| Arima, N | 1 |
| Dhakal, B | 1 |
| Veltri, LW | 1 |
| Eastwood, D | 1 |
| Craig, MD | 1 |
| Cumpston, A | 1 |
| Shillingburg, A | 1 |
| Esselman, J | 1 |
| Watkins, K | 1 |
| Pasquini, MC | 1 |
| D'Souza, A | 1 |
| Hari, P | 1 |
| Kanate, AS | 1 |
| Hamadani, M | 1 |
| Aurer, I | 2 |
| Mitrović, Z | 1 |
| Nemet, D | 2 |
| Radman, I | 2 |
| Sertić, D | 2 |
| Serventi-Seiwerth, R | 1 |
| Stern-Padovan, R | 1 |
| Santek, F | 1 |
| Nola, M | 1 |
| Mrsić, M | 2 |
| Labar, B | 2 |
| Liu, XM | 1 |
| Wang, HQ | 1 |
| Zhang, HL | 1 |
| Qiu, LH | 1 |
| Li, W | 1 |
| Li, LF | 1 |
| Cui, XZ | 1 |
| Liu, PF | 1 |
| Hao, XS | 1 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Ridola, V | 1 |
| Fawaz, O | 1 |
| Aubier, F | 1 |
| Bergeron, C | 2 |
| de Vathaire, F | 1 |
| Pichon, F | 1 |
| Orbach, D | 1 |
| Gentet, JC | 1 |
| Schmitt, C | 1 |
| Dufour, C | 1 |
| Oberlin, O | 1 |
| Lazar, AD | 1 |
| Shpilberg, O | 1 |
| Shaklai, M | 1 |
| Bairey, O | 1 |
| Hong, SJ | 1 |
| Kim, JS | 2 |
| Chang, JH | 1 |
| Kim, KM | 1 |
| Kim, SJ | 1 |
| Lee, HW | 1 |
| Cheong, JW | 1 |
| Lee, ST | 1 |
| Min, YH | 1 |
| Nishimori, H | 1 |
| Fujii, N | 1 |
| Maeda, Y | 1 |
| Matsuoka, K | 1 |
| Takenaka, K | 1 |
| Shinagawa, K | 1 |
| Ikeda, K | 1 |
| Matsuo, K | 1 |
| Harada, M | 1 |
| Tanimoto, M | 1 |
| Fridrik, MA | 2 |
| Hausmaninger, H | 2 |
| Lang, A | 1 |
| Drach, J | 1 |
| Krieger, O | 1 |
| Geissler, D | 1 |
| Michlmayr, G | 1 |
| Ulsperger, E | 1 |
| Chott, A | 2 |
| Oberaigner, W | 1 |
| Greil, R | 1 |
| Park, BB | 1 |
| Kim, WS | 1 |
| Eom, HS | 1 |
| Lee, YY | 1 |
| Oh, SJ | 1 |
| Lee, DH | 1 |
| Suh, C | 1 |
| Dincol, D | 2 |
| Buyukcelik, A | 1 |
| Dogan, M | 1 |
| Akbulut, H | 2 |
| Samur, M | 1 |
| Demirkazik, A | 2 |
| Senler, FC | 1 |
| Onur, H | 1 |
| Icli, F | 2 |
| Dührsen, U | 1 |
| Hüttmann, A | 1 |
| Jöckel, KH | 1 |
| Müller, S | 2 |
| Sandlund, JT | 1 |
| Pui, CH | 1 |
| Mahmoud, H | 1 |
| Zhou, Y | 1 |
| Lowe, E | 1 |
| Kaste, S | 1 |
| Kun, LE | 1 |
| Krasin, MJ | 1 |
| Onciu, M | 1 |
| Behm, FG | 1 |
| Ribeiro, RC | 1 |
| Razzouk, BI | 1 |
| Howard, SC | 1 |
| Metzger, ML | 1 |
| Hale, GA | 1 |
| Rencher, R | 1 |
| Graham, K | 1 |
| Hudson, MM | 1 |
| Scholz, M | 1 |
| Engert, A | 3 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 4 |
| Hasenclever, D | 1 |
| Loeffler, M | 2 |
| George, B | 1 |
| Benson, W | 2 |
| Hertzberg, MS | 2 |
| Birnbaum, T | 2 |
| Stadler, EA | 1 |
| von Baumgarten, L | 2 |
| Straube, A | 2 |
| Ong, P | 1 |
| Greulich, S | 1 |
| Schumm, J | 1 |
| Backes, M | 1 |
| Kaufmann, M | 1 |
| Bode-Erdmann, S | 1 |
| Ott, G | 1 |
| Hebart, H | 1 |
| Mahrholdt, H | 1 |
| Bochmann, K | 1 |
| Zinzani, PL | 2 |
| Tani, M | 1 |
| Molinari, AL | 1 |
| Stefoni, V | 1 |
| Zuffa, E | 1 |
| Alinari, L | 1 |
| Gabriele, A | 1 |
| Bonifazi, F | 1 |
| Salvucci, M | 1 |
| Tura, S | 1 |
| Baccarani, M | 1 |
| Lee, CK | 1 |
| de Magalhaes-Silverman, M | 1 |
| Hayashi, M | 1 |
| Schlueter, A | 1 |
| Strauss, RG | 1 |
| Hohl, RJ | 1 |
| Gingrich, RD | 1 |
| Sawada, M | 1 |
| Tsurumi, H | 1 |
| Yamada, T | 1 |
| Hara, T | 1 |
| Fukuno, K | 1 |
| Goto, H | 1 |
| Shimizu, M | 1 |
| Kasahara, S | 1 |
| Yoshikawa, T | 1 |
| Kanemura, N | 1 |
| Oyama, M | 1 |
| Takami, T | 1 |
| Moriwaki, H | 1 |
| Salar, A | 1 |
| Martino, R | 1 |
| Perea, G | 1 |
| Ribera, JM | 1 |
| López-Guillermo, A | 3 |
| Guardia, R | 1 |
| Escoda, L | 1 |
| Altés, A | 1 |
| Sierra, J | 1 |
| Montserrat, E | 3 |
| Duraković, N | 1 |
| Zupancić-Salek, S | 1 |
| Kovacević-Metelko, J | 1 |
| Bogdanić, V | 1 |
| Mikulić, M | 1 |
| Emmanouilides, C | 1 |
| Lill, M | 1 |
| Telatar, M | 1 |
| Rosenfelt, F | 1 |
| Grody, W | 1 |
| Territo, M | 1 |
| Rosen, P | 1 |
| Brinker, A | 1 |
| Kisro, J | 1 |
| Letsch, C | 1 |
| Brüggemann, SK | 1 |
| Wagner, T | 1 |
| Mottl, H | 1 |
| Bajciova, V | 1 |
| Nemec, J | 1 |
| Al Shemmari, S | 1 |
| Al Awadi, S | 1 |
| Arellano-Rodrigo, E | 1 |
| Bessell, EM | 1 |
| Nomdedeu, B | 1 |
| Graus, F | 1 |
| Sneller, V | 2 |
| Armitage, J | 1 |
| Hamlin, P | 1 |
| Kewalramani, T | 2 |
| Yahalom, J | 4 |
| Nimer, S | 1 |
| Moskowitz, CH | 5 |
| Crombie, C | 1 |
| Taper, J | 1 |
| Gottlieb, D | 1 |
| Bradstock, KF | 1 |
| Vose, J | 1 |
| Mead, G | 1 |
| Woodcock, J | 1 |
| Young, C | 1 |
| Rodeghiero, F | 1 |
| Elice, F | 1 |
| Davidson, KL | 1 |
| Devaney, MB | 1 |
| Tighe, JE | 1 |
| Rogers, SY | 1 |
| Dunlop, DJ | 1 |
| Mackie, MJ | 1 |
| Thomas, RV | 1 |
| Johnson, PR | 1 |
| Gisselbrecht, C | 2 |
| Mounier, N | 1 |
| Van Besien, K | 2 |
| Mehra, R | 2 |
| Wadehra, N | 1 |
| Stock, W | 1 |
| Khouri, I | 2 |
| Giralt, S | 4 |
| Devine, S | 1 |
| Wickrema, A | 1 |
| Peace, D | 1 |
| Sosman, J | 1 |
| Gajewski, J | 2 |
| Champlin, R | 3 |
| Pocali, B | 1 |
| De Simone, M | 1 |
| Annunziata, M | 1 |
| Palmieri, S | 1 |
| D'Amico, MR | 1 |
| Copia, C | 1 |
| Viola, A | 1 |
| Mele, G | 1 |
| Schiavone, EM | 1 |
| Ferrara, F | 1 |
| Musolino, A | 1 |
| Perrone, MA | 1 |
| Michiara, M | 1 |
| Delnevo, D | 1 |
| Franciosi, V | 1 |
| Di Blasio, B | 1 |
| Ceci, G | 1 |
| Camisa, R | 1 |
| Ardizzoni, A | 1 |
| Cocconi, G | 1 |
| Zhou, SY | 1 |
| Shi, YK | 1 |
| He, XH | 1 |
| Zhang, P | 1 |
| Dong, M | 1 |
| Huang, DZ | 1 |
| Yang, JL | 1 |
| Zhang, CG | 1 |
| Liu, P | 1 |
| Yang, S | 1 |
| Feng, FY | 1 |
| Abali, H | 2 |
| Oyan, B | 2 |
| Koc, Y | 2 |
| Kars, A | 3 |
| Barista, I | 2 |
| Uner, A | 1 |
| Turker, A | 2 |
| Demirkazik, F | 1 |
| Tekin, F | 1 |
| Tekuzman, G | 3 |
| Kansu, E | 2 |
| Chamorey, E | 1 |
| Gressin, R | 1 |
| Peyrade, F | 1 |
| Rossi, JF | 1 |
| Lepeu, G | 1 |
| Foussard, C | 1 |
| Harrousseau, JL | 1 |
| Fabbro, M | 1 |
| Richard, B | 1 |
| Delwail, V | 1 |
| Maisonneuve, H | 1 |
| Vilque, JP | 1 |
| Thyss, A | 1 |
| Ozdemir, E | 1 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 1 |
| Pereira, J | 1 |
| Bellesso, M | 1 |
| Pracchia, LF | 1 |
| Neto, AE | 1 |
| Beitler, B | 1 |
| de Almeida Macedo, MC | 1 |
| Dias, LC | 1 |
| Dorlhiac-Llacer, PE | 1 |
| Dulley, FL | 1 |
| Chamone, D | 1 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Wang, ZH | 1 |
| Ling, JY | 1 |
| Li, HH | 1 |
| Wu, XX | 1 |
| Wang, QS | 1 |
| Zhao, Y | 1 |
| Bo, J | 1 |
| Wang, SH | 1 |
| DA, WM | 1 |
| Yu, L | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Hosing, C | 1 |
| Saliba, RM | 1 |
| Körbling, M | 2 |
| Acholonu, S | 1 |
| McMannis, J | 1 |
| Anderlini, P | 2 |
| De Lima, M | 1 |
| Okoroji, GJ | 1 |
| Couriel, DR | 1 |
| Khouri, IF | 1 |
| Donato, ML | 2 |
| Bo, LJ | 1 |
| Liang, AB | 1 |
| Liu, B | 1 |
| Chen, YH | 1 |
| Wang, F | 1 |
| Jin, XP | 1 |
| Sugimoto, T | 1 |
| Matano, S | 2 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Bishton, MJ | 1 |
| Lush, RJ | 1 |
| Byrne, JL | 1 |
| Russell, NH | 1 |
| Shaw, BE | 1 |
| Haynes, AP | 1 |
| Schütt, P | 1 |
| Passon, J | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Metz, K | 1 |
| Moritz, T | 2 |
| Seeber, S | 2 |
| Nowrousian, MR | 3 |
| Nair, R | 1 |
| Prabhash, K | 1 |
| Sengar, M | 1 |
| Bakshi, A | 1 |
| Gujral, S | 1 |
| Gupta, S | 1 |
| Parikh, P | 1 |
| Hamlin, PA | 1 |
| Gabrilove, J | 1 |
| Bertino, JR | 3 |
| Portlock, CS | 4 |
| Straus, DJ | 2 |
| Gencarelli, AN | 1 |
| Nimer, SD | 4 |
| Russell, N | 2 |
| Mesters, R | 1 |
| Schubert, J | 1 |
| Boogaerts, M | 1 |
| Johnsen, HE | 1 |
| Canizo, CD | 1 |
| Baker, N | 1 |
| Barker, P | 1 |
| Skacel, T | 1 |
| Schmitz, N | 2 |
| Urün, Y | 1 |
| Oksüzoğlu, B | 1 |
| Budakoğlu, B | 1 |
| Yildirim, N | 1 |
| Güler, T | 1 |
| Ozet, G | 1 |
| Zengin, N | 1 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Arican, A | 1 |
| Maruyama, F | 3 |
| Ezaki, K | 2 |
| Miyazaki, H | 3 |
| Wakita, M | 2 |
| Nomura, T | 2 |
| Tsuzuki, M | 2 |
| Kojima, H | 2 |
| Sobue, R | 3 |
| Matsui, T | 4 |
| Ben-Dayan, D | 1 |
| Mittelman, M | 1 |
| Floru, S | 1 |
| Djaldetti, M | 1 |
| Hirano, M | 3 |
| Siegert, W | 5 |
| Nerl, C | 1 |
| Engelhard, M | 6 |
| Brittinger, G | 5 |
| Tiemann, M | 2 |
| Parwaresch, R | 2 |
| Heinz, R | 4 |
| Huhn, D | 5 |
| De Lena, M | 2 |
| Ditonno, P | 1 |
| Lorusso, V | 2 |
| Brandi, M | 1 |
| Timurian, A | 1 |
| Marzullo, F | 1 |
| Ventrella, V | 1 |
| Pellecchia, A | 1 |
| Haim, N | 4 |
| Ben-Shahar, M | 4 |
| Epelbaum, R | 4 |
| Martínez, C | 1 |
| Mateu, R | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Amill, B | 1 |
| Madoz, P | 1 |
| Portos, JM | 1 |
| Subirà, M | 1 |
| García-López, J | 1 |
| Domingo-Albós, A | 1 |
| Dreger, P | 1 |
| Klöss, M | 1 |
| Petersen, B | 1 |
| Haferlach, T | 1 |
| Löffler, H | 1 |
| Hopfinger, G | 1 |
| Koller, E | 1 |
| Schneider, B | 1 |
| Pittermann, E | 1 |
| Rodriguez, MA | 8 |
| Cabanillas, FC | 1 |
| Velasquez, W | 1 |
| Hagemeister, FB | 6 |
| McLaughlin, P | 6 |
| Swan, F | 1 |
| Romaguera, JE | 5 |
| Cairo, MS | 1 |
| Eghbali, H | 1 |
| Catry-Thomas, I | 1 |
| Soubeyran, P | 1 |
| Bonnel, C | 1 |
| Hoerni, B | 1 |
| Takeshima, M | 1 |
| Nakamura, S | 1 |
| Mochizuki, Y | 1 |
| Hattori, N | 1 |
| Kaya, H | 1 |
| Otake, S | 1 |
| Okabe, Y | 1 |
| Okumura, H | 1 |
| Yoshida, T | 1 |
| Fields, KK | 1 |
| Elfenbein, GJ | 1 |
| Lazarus, HM | 1 |
| Cooper, BW | 1 |
| Perkins, JB | 1 |
| Creger, RJ | 1 |
| Ballester, OF | 1 |
| Hiemenz, JH | 1 |
| Janssen, WE | 1 |
| Zorsky, PE | 1 |
| Reiter, A | 2 |
| Schrappe, M | 2 |
| Henze, G | 2 |
| Müller-Weihrich, S | 2 |
| Sauter, S | 1 |
| Sykora, KW | 1 |
| Ludwig, WD | 2 |
| Gadner, H | 1 |
| Riehm, H | 2 |
| Mateu, J | 1 |
| Alzamora, M | 1 |
| Franco, M | 1 |
| Buisán, MJ | 1 |
| Abate, G | 1 |
| Tafuto, S | 1 |
| Marcacci, G | 1 |
| Corazzelli, G | 1 |
| Fimiani, P | 1 |
| Monda, VM | 1 |
| Gailli, E | 1 |
| D'Andrea, P | 1 |
| Iaccarino, G | 1 |
| Buzzoni, R | 1 |
| Colleoni, M | 1 |
| Nelli, P | 1 |
| Nolè, F | 1 |
| Bajetta, E | 1 |
| Ino, T | 2 |
| Köppler, H | 2 |
| Pflüger, KH | 2 |
| Eschenbach, I | 2 |
| Pfab, R | 2 |
| Birkmann, J | 1 |
| Zeller, W | 2 |
| Holle, R | 1 |
| Steinhauer, UE | 1 |
| Gropp, C | 2 |
| Oehl, S | 2 |
| Prescott, RJ | 1 |
| Leonard, RC | 1 |
| Hickish, T | 1 |
| Roldan, A | 1 |
| Cunningham, D | 1 |
| Mansi, J | 1 |
| Ashley, S | 1 |
| Nicolson, V | 1 |
| Gore, ME | 1 |
| Catovsky, D | 1 |
| Smith, IE | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Walther, J | 1 |
| Wilmanns, W | 2 |
| Gerhartz, HH | 3 |
| Linkesch, W | 1 |
| Stöger, M | 1 |
| Sill, H | 1 |
| Neubauer, M | 1 |
| Seewann, HL | 1 |
| Klocker, J | 1 |
| Haidinger, R | 1 |
| Schiller, L | 1 |
| Pont, J | 1 |
| Raudaschl, G | 1 |
| Falk, M | 1 |
| Radaszkiewicz, T | 1 |
| Cheng, AL | 1 |
| Goss, P | 1 |
| Shepherd, F | 1 |
| Scott, JG | 2 |
| Baker, M | 1 |
| Sutton, D | 2 |
| Sutcliffe, S | 2 |
| Weintraub, M | 1 |
| Adde, MA | 1 |
| Venzon, DJ | 1 |
| Shad, AT | 1 |
| Horak, ID | 2 |
| Neely, JE | 1 |
| Seibel, NL | 1 |
| Gootenberg, J | 2 |
| Arndt, C | 2 |
| Nieder, ML | 1 |
| Magrath, IT | 1 |
| Magrath, I | 2 |
| Adde, M | 2 |
| Shad, A | 1 |
| Venzon, D | 1 |
| Seibel, N | 1 |
| Neely, J | 1 |
| Nieder, M | 1 |
| Jaffe, E | 1 |
| Wittes, RA | 1 |
| Stamatoullas, A | 1 |
| Fruchart, C | 1 |
| Bastit, D | 1 |
| Boulet, D | 1 |
| Moncondult, M | 1 |
| Piguet, H | 1 |
| Tilly, H | 2 |
| Pettengell, R | 1 |
| Radford, JA | 1 |
| Morgenstern, GR | 1 |
| Scarffe, JH | 1 |
| Harris, M | 1 |
| Woll, PJ | 1 |
| Deakin, DP | 1 |
| Ryder, D | 1 |
| Wilkinson, PM | 1 |
| Crowther, D | 1 |
| Enblad, G | 2 |
| Hagberg, H | 2 |
| Glimelius, B | 2 |
| Wong, ET | 1 |
| O'Brien, JP | 2 |
| DeAngelis, LM | 1 |
| Pohlman, B | 1 |
| Vose, JM | 1 |
| Coiffier, B | 2 |
| Voûte, PA | 1 |
| van den Berg, H | 1 |
| Behrendt, H | 1 |
| Michiels, E | 1 |
| de Kraker, J | 1 |
| Schnell, R | 2 |
| Küpper, F | 1 |
| Reiser, M | 2 |
| Wilhelm, M | 2 |
| Lathan, B | 1 |
| Baltes-Engler, S | 1 |
| Winterhalter, B | 1 |
| Scheulen, ME | 1 |
| Dederichs, B | 1 |
| Tesch, H | 1 |
| Wörmann, B | 2 |
| Engelhardt, M | 1 |
| Winkler, J | 1 |
| Waller, C | 1 |
| Lange, W | 1 |
| Mertelsmann, R | 1 |
| Henschler, R | 1 |
| Mundt, AJ | 1 |
| Williams, SF | 1 |
| Hallahan, D | 1 |
| Rodriguez-Monge, EJ | 1 |
| Cabanillas, F | 9 |
| Faraggi, D | 1 |
| Tsuri-Etzioni, A | 1 |
| Leviov, M | 1 |
| Garay, G | 1 |
| Dupont, J | 1 |
| Dragosky, M | 1 |
| Nucifora, E | 1 |
| Cacchione, R | 1 |
| Schnidrig, P | 1 |
| Fernández, J | 1 |
| Riveros, D | 1 |
| Noviello, V | 1 |
| Bèguelin, R | 1 |
| Campestri, R | 1 |
| Albera, C | 1 |
| Nicastro, M | 1 |
| Triguboff, E | 1 |
| Aydogdu, I | 1 |
| Koc, H | 1 |
| Ilhan, O | 1 |
| Gurman, G | 1 |
| Akan, H | 1 |
| Beksac, M | 1 |
| Konuk, N | 1 |
| Uysal, A | 1 |
| Ozerol, E | 1 |
| Kleiner, S | 1 |
| Kirsch, A | 1 |
| Schwaner, I | 1 |
| Kingreen, D | 1 |
| Schwella, N | 1 |
| Aurlien, E | 1 |
| Holte, H | 1 |
| Pharo, A | 1 |
| Kvaløy, S | 1 |
| Jakobsen, E | 1 |
| Smeland, EB | 1 |
| Kvalheim, G | 1 |
| Rodriguez-Diaz Pavón, J | 1 |
| Dong, K | 1 |
| Moon, T | 1 |
| García-Conde, J | 1 |
| Alvarez-Carmona, AM | 1 |
| León, P | 1 |
| Maldonado, J | 1 |
| Alcalá, A | 1 |
| Zubizarreta, A | 1 |
| Sancho-Tello, R | 1 |
| Carbonell, F | 1 |
| Contreras, E | 1 |
| Besses, C | 1 |
| Hernando, A | 1 |
| Fontanillas, M | 1 |
| Jhanwar-Uniyal, M | 1 |
| Gulati, SC | 1 |
| Celik, I | 1 |
| Güler, N | 1 |
| Ozyilkan, O | 1 |
| Hayran, M | 1 |
| Firat, D | 1 |
| Yule, SM | 1 |
| Price, L | 1 |
| Pearson, AD | 1 |
| Boddy, AV | 1 |
| Mayer, J | 1 |
| Korístek, Z | 1 |
| Vásová, I | 1 |
| Müllerová, I | 1 |
| Král, Z | 1 |
| Navrátil, M | 1 |
| Klabusay, M | 1 |
| Vorlícek, J | 1 |
| Vodvárka, P | 1 |
| Hejlová, N | 1 |
| Penka, M | 1 |
| Krahulcová, E | 1 |
| Tomíska, M | 1 |
| Adam, Z | 1 |
| Hájek, R | 1 |
| Straub, G | 1 |
| Borchmann, P | 1 |
| Ubelacker, R | 1 |
| Münch, R | 1 |
| Itoh, K | 1 |
| Igarashi, T | 1 |
| Ohtsu, T | 1 |
| Wakita, H | 1 |
| Watanabe, Y | 1 |
| Fujii, H | 1 |
| Minami, H | 1 |
| Sasaki, Y | 1 |
| Drumea, K | 1 |
| Plantier-Colcher, I | 1 |
| Dupriez, B | 2 |
| Simon, M | 1 |
| Detourmignies, L | 1 |
| Jouet, JP | 1 |
| Fenaux, P | 1 |
| Bauters, F | 1 |
| Morel, P | 1 |
| Bachier, C | 1 |
| Preti, H | 1 |
| Sarris, AH | 2 |
| Weber, D | 1 |
| Younes, A | 5 |
| Kung, FH | 1 |
| Harris, MB | 1 |
| Krischer, JP | 1 |
| Rodriguez, J | 2 |
| Fayad, L | 1 |
| Santiago, M | 1 |
| Hess, M | 1 |
| Romaguera, J | 1 |
| Glassman, JR | 2 |
| Elkin, N | 1 |
| Reinhardt, W | 1 |
| Sauter, V | 1 |
| Jockenhövel, F | 1 |
| Kummer, G | 1 |
| Uppenkamp, M | 1 |
| Witzke, O | 1 |
| Philipp, T | 1 |
| Reinwein, D | 1 |
| Mann, K | 1 |
| McQuaker, I | 1 |
| Haynes, A | 1 |
| Stainer, C | 1 |
| Byrne, J | 1 |
| Yakisan, E | 1 |
| Zimmermann, M | 1 |
| Mann, G | 1 |
| Ebell, W | 1 |
| Klingebiel, T | 1 |
| Graf, N | 1 |
| Kremens, B | 1 |
| Plüss, HJ | 1 |
| Zintl, F | 1 |
| Hedrick, EE | 2 |
| Hunte, S | 2 |
| Coady-Lyons, N | 1 |
| Agus, DB | 1 |
| Goy, A | 1 |
| Jurcic, J | 1 |
| Noy, A | 1 |
| O'Brien, J | 1 |
| Straus, DS | 1 |
| Childs, B | 1 |
| Frank, R | 1 |
| Filippa, D | 1 |
| Louie, D | 1 |
| Preti, A | 1 |
| Inoue, R | 1 |
| Natazuka, T | 1 |
| Shimoyama, M | 1 |
| Tamekane, A | 1 |
| Kajimoto, Y | 1 |
| Iwata, N | 1 |
| Matsuoka, H | 1 |
| Chihara, K | 1 |
| King, K | 1 |
| Champlin, RE | 1 |
| Van Besien, KW | 1 |
| Gajewski, JG | 1 |
| Lauppe, J | 1 |
| Durett, A | 1 |
| Andersson, B | 2 |
| Hagemeister, F | 1 |
| Sarris, A | 2 |
| Ippoliti, C | 1 |
| Blamble, DA | 1 |
| Hester, J | 1 |
| Gee, A | 1 |
| McBride, NC | 1 |
| Ward, MC | 1 |
| Mills, MJ | 1 |
| Eden, AG | 1 |
| Hughes, A | 1 |
| Cavenagh, JD | 1 |
| Lamont, A | 1 |
| Newland, AC | 1 |
| Kelsey, SM | 1 |
| Vela-Ojeda, J | 1 |
| Tripp-Villanueva, F | 1 |
| Montiel-Cervantes, L | 1 |
| Sánchez-Cortés, E | 1 |
| Ayala-Sánchez, M | 1 |
| Guevara-Moreno, ME | 1 |
| García-León, LD | 1 |
| Rosas-Cabral, A | 1 |
| Esparza, MA | 1 |
| González-Llaven, J | 1 |
| Hołowiecki, J | 1 |
| Wojciechowska, M | 1 |
| Krawczyk-Kuliś, M | 1 |
| Wojnar, J | 1 |
| Kachel, L | 1 |
| Kata, D | 1 |
| Markiewicz, M | 1 |
| Donnelly, GB | 1 |
| Priovolos, AC | 1 |
| Qin, J | 1 |
| Lyons, NC | 1 |
| Skovlund, E | 1 |
| Fenstad, GU | 1 |
| Rodriguez, A | 1 |
| Tomany, S | 1 |
| Donato, M | 1 |
| Fiedler, R | 1 |
| Baumann, F | 1 |
| Deschler, B | 1 |
| Osten, B | 1 |
| Wilder, RB | 1 |
| Tucker, SL | 1 |
| Ha, CS | 1 |
| Hess, MA | 1 |
| Cabanillas, FF | 1 |
| Cox, JD | 1 |
| Coleman, M | 1 |
| Leonard, J | 1 |
| Shuster, MW | 1 |
| Kaufman, TP | 1 |
| Vellenga, E | 1 |
| van Agthoven, M | 1 |
| Croockewit, AJ | 1 |
| Verdonck, LF | 1 |
| Wijermans, PJ | 1 |
| van Oers, MH | 1 |
| Volkers, CP | 1 |
| van Imhoff, GW | 1 |
| Kingma, T | 1 |
| Uyl-de Groot, CA | 1 |
| Fibbe, WE | 1 |
| Lee, EJ | 1 |
| Petroni, GR | 1 |
| Schiffer, CA | 1 |
| Freter, CE | 1 |
| Johnson, JL | 1 |
| Barcos, M | 1 |
| Frizzera, G | 1 |
| Bloomfield, CD | 1 |
| Peterson, BA | 1 |
| Jain, S | 1 |
| Moger, V | 1 |
| Kumari, S | 1 |
| Varma, S | 1 |
| Bosly, A | 1 |
| Lepage, E | 1 |
| Fillet, G | 1 |
| Herbrecht, R | 3 |
| Divine, M | 1 |
| Nouvel, C | 1 |
| Deconninck, E | 1 |
| Bordessoule, D | 1 |
| Gaulard, P | 1 |
| Primavera, A | 1 |
| Audenino, D | 1 |
| Cocito, L | 1 |
| Moskowitz, C | 1 |
| Shimizu, K | 1 |
| Shinkai, K | 1 |
| Steinke, B | 3 |
| Bross, K | 2 |
| Reinold, HM | 2 |
| Heim, ME | 3 |
| Schalk, KP | 1 |
| Heidemann, E | 2 |
| Josten, K | 2 |
| Arnold, H | 2 |
| Manegold, C | 1 |
| Hoffman, I | 1 |
| Damonte, JC | 1 |
| Dufour, P | 2 |
| Maloisel, F | 1 |
| Liu, KL | 1 |
| Ortiz, S | 1 |
| Bergerat, JP | 2 |
| Oberling, F | 2 |
| Goss, PE | 2 |
| Miller, LJ | 1 |
| Eaton, VE | 1 |
| Case, DC | 2 |
| Santarelli, MT | 1 |
| Carey, RW | 1 |
| Anderson, J | 2 |
| Gottlieb, A | 2 |
| Rosenblatt, E | 1 |
| Wollner, M | 1 |
| Robinson, E | 1 |
| Anders, CH | 1 |
| Niederle, N | 1 |
| Nagel-Hiemke, M | 1 |
| Schmidt, CG | 2 |
| Meusers, P | 3 |
| Brack, N | 1 |
| Dornoff, W | 1 |
| Enne, W | 2 |
| Gassmann, W | 1 |
| Gerhartz, H | 2 |
| Hallek, M | 1 |
| Heise, J | 1 |
| Gutiérrez, J | 1 |
| Osorio, G | 1 |
| García, H | 1 |
| Vacarezza, R | 1 |
| Cao, C | 1 |
| Paradiso, A | 1 |
| Guida, M | 1 |
| Berardi, F | 1 |
| Mirza, MR | 1 |
| Brincker, H | 1 |
| Shepherd, FA | 1 |
| Warner, E | 1 |
| Baker, MA | 1 |
| Farquharson, HA | 1 |
| Buick, S | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Bruntsch, U | 1 |
| Steinhauer, EU | 1 |
| Lötzke, E | 1 |
| Lindemalm, C | 1 |
| Tada, A | 1 |
| Ohnoshi, T | 1 |
| Hayashi, K | 1 |
| Ueoka, H | 1 |
| Ueno, K | 1 |
| Murashima, M | 1 |
| Mizuta, J | 1 |
| Yoshida, M | 1 |
| Kimura, I | 1 |
| Thiel, E | 3 |
| Dörken, B | 1 |
| Engert, W | 1 |
| Fuchs, R | 1 |
| Hagen-Aukamp, CH | 1 |
| Neubauer, A | 1 |
| Stacher, A | 2 |
| Krüger, HU | 1 |
| Kraft, H | 1 |
| Günther, E | 1 |
| Busch, FW | 1 |
| von Kalle, AK | 1 |
| Schaadt, M | 1 |
| Kraft, A | 1 |
| Löffler, B | 1 |
| Richter, C | 1 |
| Hofmann, I | 1 |
| Garcia, JJ | 1 |
| Duclos, B | 1 |
| Meier, CR | 1 |
| Schoetensack, B | 1 |
| Anders, C | 1 |
| Höffken, K | 1 |
| Osieka, R | 1 |
| Sampi, K | 1 |
| Masaoka, T | 1 |
| Takagi, T | 1 |
| Sakamoto, S | 1 |
| Mikuni, C | 1 |
| Kano, Y | 1 |
| Gad-el-Mawla, N | 1 |
| Hussein, MH | 1 |
| Abdel-Hadi, S | 1 |
| el-Taneer, O | 1 |
| Sangster, G | 1 |
| Patton, WN | 1 |
| Harris, RI | 1 |
| Grieve, RJ | 1 |
| Leyland, MJ | 1 |
| Ervin, TJ | 1 |
| Li, GC | 1 |
| Brock, N | 1 |
| Li, JQ | 1 |
| Guan, ZZ | 1 |
| He, YJ | 1 |
| Norberg, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma[NCT00517894] | 0 participants | Expanded Access | No longer available | ||||
| Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas[NCT00554164] | Phase 3 | 1,073 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| A Single Center, Prospective Study to Compare the Quality and Quantity of the Cellular Content of M-PRP Harvested After Peripheral Mobilization of Progenitor Cells Using Filgrastim Versus Pegfilgrastim[NCT05573386] | 10 participants (Anticipated) | Observational | 2021-08-09 | Recruiting | |||
| A Randomised, Multi-Centre, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Non-Hodgkin's Lymphoma[NCT00117455] | Phase 2 | 0 participants | Interventional | Completed | |||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China[NCT02405676] | Phase 2/Phase 3 | 200 participants (Anticipated) | Interventional | 2015-01-31 | Active, not recruiting | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494] | Phase 2 | 134 participants (Actual) | Interventional | 1992-05-31 | Completed | ||
| PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA[NCT00018954] | Phase 2 | 0 participants | Interventional | 1992-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for ifosfamide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Extra-nodal Cytokeratin-Positive Interstitial Reticulum Cell Sarcoma Presenting as a Colonic Polyp: Report of a Rare Case with Review of Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colon; Col | 2020 |
Current role and future perspectives for ifosfamide in the treatment of malignant non-Hodgkin's lymphoma--results from an expert meeting.
Topics: Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 2003 |
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Etoposide; Fo | 2003 |
Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Epirubicin; Etoposide; Hod | 2003 |
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Mo | 2003 |
Ifosfamide in hematological malignancies of adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Hematologic Neoplasms; Hodgkin Disease; | 2003 |
Improving second-line therapy in aggressive non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Transverse nail ridgings (Beau's lines) induced by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dexame | 1994 |
[Malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 1994 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L | 1995 |
[Recent progress on therapy of malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Humans; Ifosfa | 1993 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Ifosfamide in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Ste | 1996 |
Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 1996 |
Ifosfamide in the treatment of lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 1996 |
Factors that influence prognosis of intermediate-grade lymphomas at relapse.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cisplatin; | 1996 |
Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials a | 2000 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
New perspectives in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Ifosfamide; Lympho | 1992 |
Ifosfamide-induced neurotoxicity: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Humans; Ifos | 1992 |
European experience with ifosfamide in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Etoposide; Europe; Hodgkin Disease; Human | 1989 |
79 trials available for ifosfamide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; L | 2023 |
Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 2013 |
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2016 |
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free S | 2008 |
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2010 |
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2010 |
Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide | 2012 |
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy | 2002 |
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cycloph | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen | 2002 |
New insights into the clinical pharmacokinetics of trofosfamide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Availability; Cyclophos | 2002 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2003 |
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Etoposide; Hum | 2004 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2005 |
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; | 2005 |
Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cytarabine; Developing Co | 2006 |
Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopo | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera | 2007 |
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose | 2007 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1994 |
CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocol | 1995 |
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cispl | 1995 |
Peripheral blood stem cell mobilization following salvage chemotherapy (IAPVP-16) plus granulocyte colony-stimulating factor and autografting for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Gr | 1995 |
[MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifos | 1995 |
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1995 |
Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cis | 1994 |
Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Lymphoma, N | 1993 |
EPIC: an effective low toxicity regimen for relapsing lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug A | 1993 |
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 1996 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Fe | 1995 |
Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1996 |
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 1996 |
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diseas | 1996 |
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Combined Mod | 1996 |
Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dox | 1996 |
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Humans | 1997 |
Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cell Separa | 1997 |
Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy P | 1997 |
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; | 1997 |
High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran | 1997 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; | 1998 |
[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hem
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Data Interpretation, S | 1998 |
Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 1998 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etopos | 1998 |
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dexamethas | 1998 |
Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Fem | 1998 |
Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; F | 1999 |
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1999 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabin | 1998 |
Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Movement; | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; | 1999 |
Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cyclophosphami | 2000 |
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; | 1999 |
Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 1999 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyc | 2000 |
Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Female; Granulocyte Colon | 2000 |
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Follow-Up S | 2001 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2001 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Re | 2001 |
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi- | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug | 2001 |
Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1992 |
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1992 |
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Ifo | 1991 |
Sequential versus alternating chemotherapy for high-grade non-Hodgkin's lymphomas: preliminary results of a phase III multicentre trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Re | 1990 |
German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
[Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cy | 1989 |
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials | 1989 |
[Aclarubicin-combined combination chemotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Drug Resi | 1989 |
94 other studies available for ifosfamide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2022 |
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposid | 2022 |
PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma | 2023 |
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 2020 |
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deo | 2020 |
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2015 |
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Do | 2016 |
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dexamethasone; | 2016 |
Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Topics: Antigens, CD34; Antineoplastic Agents; Epirubicin; Etoposide; Hematopoietic Stem Cell Mobilization; | 2016 |
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Tra | 2016 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp | 2009 |
Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Fe | 2009 |
A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Central Nervous System Neoplasms; Cy | 2009 |
Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexameth | 2009 |
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; D | 2011 |
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Etoposide; Hodgkin Disease; Hu | 2011 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System N | 2012 |
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2013 |
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 2002 |
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfami | 2002 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide | 2003 |
Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antine | 2003 |
Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Etop | 2004 |
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 2005 |
[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dexametha | 2005 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Daca | 2006 |
[IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxo | 2007 |
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
[Increased blood cell destruction during vigorous regeneration of bone marrow after CAMBO-VIP chemotherapy for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count | 1994 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marr | 1995 |
Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Mar | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine | 1995 |
Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophospha | 1993 |
[Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Femal | 1994 |
Ifosfamide extravasation.
Topics: Chondroitinsulfatases; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Ifosfa | 1994 |
Three-year results of MIM salvage treatment for refractory/relapsed intermediate grade NHL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrex | 1995 |
[Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; | 1994 |
High-dose carboplatin, etoposide and ifosfamide and autologous stem cell rescue in the treatment of non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined M | 1993 |
IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Granulocyte-Macr | 1993 |
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cyclophosphamide; Cyta | 1996 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined M | 1996 |
Ifosfamide in the treatment of pediatric malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1996 |
High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposi | 1997 |
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free S | 1997 |
Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 1997 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1998 |
p53 gene mutation in the bone-marrow of a patient with diffuse mixed cell type lymphoma at diagnosis predicting eventual progression to large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; Disease Progr | 1998 |
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl | 1997 |
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1999 |
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposi | 1999 |
Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide).
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexameth | 1999 |
Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
Topics: Adult; Antigens, CD34; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematop | 1999 |
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Eto | 2000 |
Should we always choose a nonparametric test when comparing two apparently nonnormal distributions?
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dat | 2001 |
Haemoperfusion combined with haemodialysis in ifosfamide intoxication.
Topics: Adult; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Hemoperfusion; Humans; Ifosfami | 2001 |
Ifosfamide induced encephalopathy following chemotherapy of Non-Hodgkin's Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Lymphoma, Non-H | 2001 |
Ifosfamide encephalopathy and nonconvulsive status epilepticus.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Electroencephalography; Epileps | 2002 |
Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administrat | 2002 |
Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclo | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin | 1992 |
Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamid | 1992 |
Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexametha | 1992 |
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; | 1991 |
[Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; F | 1991 |
Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; | 1991 |
Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; | 1991 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; H | 1990 |
[Combination chemotherapy of diffuse large-cell non-Hodgkin's lymphoma--superiority of the adriamycin combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1987 |
Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1988 |
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 1989 |
Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1989 |
Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1989 |
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Evaluation; Etoposide | 1989 |
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Hematologic Diseases; Hematuria; Humans | 1988 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Ifosfamide combinations in salvage treatment of non-Hodgkin lymphoma.
Topics: Cytarabine; Doxorubicin; Drug Evaluation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 1986 |